In this study, we examined the cost-effectiveness of routine
application of mupirocin at the catheter exit site in PD recipients
during the first 12 months of dialysis. The results of a base case
analysis demonstrated that the mupirocin group dominated the
control group,with lower costs per patient, greater QALYs gained, and
a reduced gram-positive infection related mortality rate. Sensitivity
analyses suggested that the base case analysis findings were robust
throughout a wide range of clinical, cost, and utility inputs in the
decision-tree model.